Scientific publications

SEOM clinical guideline for the management of malignant melanoma (2017)

Jan 1, 2018 | Magazine: Clinical & Translational Oncology

A Berrocal  1 , A Arance  2 , V E Castellon  3 , L de la Cruz  4 , E Espinosa  5 , M G Cao  6 , J L G Larriba  7 , I Márquez-Rodas  8 , A Soria  9 , S M Algarra  10


All melanoma suspected patients must be confirmed histologically and resected. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon could be offered for patients with high-risk melanoma and in selected cases radiotherapy can be added.

Metastatic melanoma treatment is guided by mutational BRAF status. BRAF wild type patients must receive anti-PD1 containing therapy and BRAF mutated patients BRAF/MEK inhibitors or anti-PD1 containing therapy. Up to 10 years follow up is reasonable for melanoma patients with dermatologic examinations and physical exams.

CITATION  Clin Transl Oncol. 2018 Jan;20(1):69-74. doi: 10.1007/s12094-017-1768-1.  Epub 2017 Nov 7.